Meeting
2017 ASCO Annual Meeting
A call for global harmonization of phase I oncology trials: Results from two parallel, first-in-human phase I studies of DS-7423, an oral PI3K/mTOR dual inhibitor in advanced solid tumors conducted in the United States and Japan.
Authors
Tomoya Yokota
Shizuoka Cancer Center, Shizuoka, Japan
Tomoya Yokota , Johanna C. Bendell , Patricia LoRusso , Takahiro Tsushima , Ved Desai , Hirotsugu Kenmotsu , Junichiro Watanabe , Akira Ono , Bhavani G. Murugesan , Joseph Silva , Tateaki Naito , Jonathan Greenberg , Prasanna Kumar , Yibin Wang , Takahiro Jikoh , Ryota Shiga , Alan Loh Ho , Mrinal M. Gounder
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics
Track
Developmental Therapeutics and Translational Research
Sub Track
Conduct of Clinical Research
Clinical Trial Registration Number
NCT01364844, Japic CTI, 12766
Citation
J Clin Oncol 35, 2017 (suppl; abstr 2536)
DOI
10.1200/JCO.2017.35.15_suppl.2536
Abstract #
2536
Poster Bd #
28
Abstract Disclosures
Similar Posters
Poster
2013 ASCO Annual Meeting
A phase I, dose-escalation trial of continuous and pulsed-dose afatinib (A) combined with pemetrexed (P) in patients (pts) with advanced solid tumors: Final analysis.
First Author: Quincy S. Chu
Poster
2017 ASCO Annual Meeting
First-in-human phase I study of an oral HSP90 inhibitor, TAS-116, in advanced solid tumors.
First Author: Noriko Yanagitani
Poster
2015 ASCO Annual Meeting
First-in-human phase I trial of the PI3Kb-selective inhibitor SAR260301 in patients with advanced solid tumors (NCT01673737).
First Author: Philippe L. Bedard
Poster
2013 ASCO Annual Meeting
Safety and efficacy of nintedanib (BIBF 1120) plus pemetrexed in Japanese patients with advanced or recurrent non-small cell lung cancer (NSCLC): A phase I study.
First Author: Haruko Daga